This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Corona Virus Infection Among Liver Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04565782
Recruitment Status : Unknown
Verified September 2020 by Dr. Nahed A. Makhlouf, Assiut University.
Recruitment status was:  Recruiting
First Posted : September 25, 2020
Last Update Posted : September 25, 2020
Information provided by (Responsible Party):
Dr. Nahed A. Makhlouf, Assiut University

Brief Summary:

A new strain of coronavirus that caused severe respiratory disease in infected individuals was initially identified in China's Wuhan City in December 2019. Severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2), which was responsible for the corona virus infectious disease-2019 (COVID-19).The World Health Organization declared that COVID-19 was a Public Health Emergency of International Concern on January 30,2020.

The impact of COVID-19 in liver recipients remains largely unknown but accumulating experience is going on.

Liver transplant recipients should have been classified as a risk group and should have received regular surveillance for COVID-19 throughout the pandemic.

Some reports suggest decreasing immunosuppression for infected recipients, if no recent rejection episodes. Paradoxically, others suggest that a reactive immune response might be the cause for severe tissue damage, and that immunosuppression might be protective from the postulated cytokine storm.

Some studies stated that the LT patients who are permanently on immunosuppressants could be particularly susceptible to SARS-CoV-2, and their prognosis could be worse in comparison to the normal population. They recommended that LT recipients should be closely monitored for SARS-CoV-2.

The LT society of India (LTSI) highlighted the potential of LT recipients as asymptomatic carriers and source of viral spread, and that SARS-CoV-2 can be transmitted to LT recipients. There are insufficient data on the relationship between immunosuppressive therapy and COVID-19 in LT recipients during this pandemic. However, the Beijing working party for liver transplantation suggested that LT recipients who were infected with SARS-CoV-2 should be treated with steroids for a short period to reduce the severity of pneumonia.

They also suggested that immunosuppressive therapies should be continued for both patients with mild COVID-19 and those who were not infected by the virus, and calcineurin inhibitor treatment dosage should be reduced in moderate to severe cases.

Neutralizing antibodies (NAbs) play an important role in virus clearance and have been considered as a key immune product for protection or treatment against viral diseases. Virus-specific NAbs, induced through either infection or vaccination, have the ability to block viral infection. SARS-CoV -2 specific NAbs reached their peak in patients from day 10-15 after the onset of the disease and remained stable thereafter in the patients. Antibodies targeting on different domains of S protein, including S1, RBD, and S2, may all contribute to the neutralization.

Al-Rajhi Liver Center is the only liver transplantation center in Upper Egypt that performed only 51 living donor liver transplantation (LDLT) cases since 2014, but it was used as isolation Hospital for COVID-19 cases from March to July, 2020. Communication with liver transplant cases during that period was via Telemedicine. Resuming usual Hospital activity as Tertiary Liver Center occurred in 15 August 2020. Similarly, other Hospitals in Egypt were designated as COVID-19 isolation Hospitals.

Condition or disease
SARS-CoV Infection Corona Virus Infection Liver Transplant Recipient COVID-19

Detailed Description:
  1. Liver Transplant recipients in 3 liver transplant centers will answer survey including 21 questions (14 questions covers the demographic data, date since the operation and immunosuppressant medications and 11 questions related to Corona virus infection). (SARS-CoV-2 infection will be defined according to the Ministry of Health and population definitions of suspected and confirmed cases).
  2. Doing serological test searching for Neutralizing Ab against SARS-Corona virus 2 in the liver transplant recipients who accepted to give blood sample.

(It can be detected by Electrochemiluminescence immunoassay (ECLIA) method.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Corona Virus Infection Among Liver Transplant Recipients: A Multicenter Study
Actual Study Start Date : September 15, 2020
Estimated Primary Completion Date : November 1, 2020
Estimated Study Completion Date : December 31, 2020

Primary Outcome Measures :
  1. The occurrence of corona virus infection (confirmed or suspected) among liver transplant recipients [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. The presence of Neutralizing Ab against SARS-Corona virus 2 among liver transplant recipients whether who give symptoms for corona virus or asymptomatic and who accept to give blood sample [ Time Frame: 2 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Liver transplant recipients in 3 Liver Transplant Centers in Egypt and who accept to participate in the study.

Inclusion Criteria:

-Liver transplant recipients in 3 Liver Transplant Centers in Egypt and who accept to participate in the study

Exclusion Criteria:

  • Those who refuse to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04565782

Layout table for location information
Assiut University Recruiting
Assiut, Egypt
Contact: Nahed Makhlouf, Professor    01003611626   
Contact: Mohamed A Medhat, MD    01000493632   
Sub-Investigator: Amal A Mahmoud, MD         
Sub-Investigator: Mohammed A Medhat, MD         
Sub-Investigator: Bashir A Fadel, MD         
Principal Investigator: Nahed A Makhlouf, Professor         
Sub-Investigator: Rasha O Refaay, Professor         
Sponsors and Collaborators
Assiut University
Layout table for additonal information
Responsible Party: Dr. Nahed A. Makhlouf, Professor of Tropical Medicine and Gastroenterology, Assiut University Identifier: NCT04565782    
Other Study ID Numbers: 17300475
First Posted: September 25, 2020    Key Record Dates
Last Update Posted: September 25, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Virus Diseases
Coronavirus Infections
Severe Acute Respiratory Syndrome
Disease Attributes
Pathologic Processes
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Respiratory Tract Infections
Respiratory Tract Diseases